U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Vaping Xtreme, LLC - 613230 - 07/09/2021
  1. Warning Letters

CLOSEOUT LETTER

Vaping Xtreme, LLC MARCS-CMS 613230 —

Delivery Method:
VIA UPS and Electronic Mail
Reference #:
RW2101496
Product:
Tobacco
Recipient:
Vaping Xtreme, LLC

13803 Independence Blvd.
Suite I
Indian Trail, NC 28079
United States

mark@vapingxtreme.com
Issuing Office:
Center for Tobacco Products

United States

The United States Food and Drug Administration’s (FDA) Center for Tobacco Products has completed an evaluation of your corrective actions included in your response dated March 1, 2021, in response to our Warning Letter dated February 12, 2021. Based on our evaluation, it appears that you have taken steps to address the violations contained in the Warning Letter regarding the website https://vapingxtreme.com.

However, our surveillance shows you continue to offer for sale to customers in the United States other tobacco products that may be subject to market authorization requirements. FDA encourages you to discuss with your suppliers the current status of any particular tobacco product’s marketing application or any product’s marketing authorization. For additional information regarding currently marketed tobacco products that a company generally might manufacture, distribute, or sell without risking FDA enforcement, please visit our website https://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/deemed-new-tobacco-product-applications-lists?utm_medium=email&utm_source=govdelivery#list%20of%20deemed.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.

Sincerely,
/S/
Nathan Everly
Branch Chief
Division of Promotion, Advertising, and Labeling
Office of Compliance and Enforcement
Center for Tobacco Products


VIA UPS and Electronic Mail

cc:

Ferguson, Hayes, Hawkins & DeMay, PLLC
Attn: Brian Hayes
45 Church St. S
Concord, NC 28026
hayes@concordlawyers.com

GoDaddy.com, LLC
abuse@godaddy.com

Google, LLC
google-cloud-compliance@google.com

Back to Top